## Results
### Primary Efficacy Endpoints
\begin{table}
\begin{tabular}{c c c c c c c c c c c c c} \hline \hline \multirow{2}{*}{**Change**} & \multirow{2}{*}{**Lesions**} & \multirow{2}{*}{**Treatment**} & \multicolumn{3}{c}{**Treated Side**} & \multicolumn{3}{c}{**Untreated Side**} & \multicolumn{3}{c}{**A**} \\ \cline{3-14}  & & & **m** & **95\% CI** & **m** & **95\% CI** & **m** & **95\% CI** & **m** & **95\% CI** & **_p_ \\ \hline \multirow{4}{*}{\begin{tabular}{c} Last \\ treatment— \\ baseline \\ \end{tabular} } & \multirow{4}{*}{inflammatory} & \multirow{4}{*}{8} & \multirow{4}{*}{–4.8} & \multirow{4}{*}{–8.5} & \multirow{4}{*}{–1.1} & \multirow{4}{*}{–5.9} & \multirow{4}{*}{–6.7} & \multirow{4}{*}{–0.8} & \multirow{4}{*}{0.5} & \multirow{4}{*}{–1.8} & \multirow{4}{*}{2.8} & \multirow{4}{*}{0.669} \\  & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & & & \\ \hline \multirow{4}{*}{\begin{tabular}{c} Two-week \\ follow-up to \\ baseline \\ \end{tabular} } & \multirow{4}{*}{8} & \multirow{4}{*}{–7.0} & \multirow{4}{*}{–3.0} & \multirow{4}{*}{–4.8} & \multirow{4}{*}{–8.7} & \multirow{4}{*}{–0.8} & \multirow{4}{*}{2.2} & \multirow{4}{*}{–2.3} & \multirow{4}{*}{6.8} & \multirow{4}{*}{0.323} \\  & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & & \\ \hline \multirow{4}{*}{\begin{tabular}{c} Four-week \\ follow-up to \\ baseline \\ \end{tabular} } & \multirow{4}{*}{8} & \multirow{4}{*}{–8.7} & \multirow{4}{*}{–7.3} & \multirow{4}{*}{–7.3} & \multirow{4}{*}{–1.5} & \multirow{4}{*}{–1.1} & \multirow{4}{*}{3.5} & \multirow{4}{*}{–2.2} & \multirow{4}{*}{4.9} & \multirow{4}{*}{0.449} \\  & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & & \\ \hline \multirow{4}{*}{\
\begin{tabular}{c} Non- \\ inflammatory \\ \end{tabular} } & \multirow{4}{*}{8} & \multirow{4}{*}{–8.4} & \multirow{4}{*}{–1.0} & \multirow{4}{*}{–1.5} & \multirow{4}{*}{–4.9} & \multirow{4}{*}{–1.0} & \multirow{4}{*}{1.5} & \multirow{4}{*}{–1.0} & \multirow{4}{*}{3.5} & \multirow{4}{*}{0.254} \\  & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & \\ \cline{1-1} \cline{6-14}  & & & & & & & & & & & & & \\ \hline \multirow{4}{*}{
\begin{tabular}{c} Mixed linear models (MLMs) were used to compare the change in the number of lesions between the treated and the untreated side. MLMs additionally included the number of applied plasma treatments and the number of lesions at baseline. Presented are the estimated/adjusted means including 95% confidence interval (CI) out of six separate MLMs (two types of lesions \(\times\) three time points). For both types of lesions, the mean change in the number of lesions is additionally presented as mean change in percentage. Moreover, mean differences (\(\Delta\)) of mean change in the number of lesions including 95% CI are presented. In total, 29 patients had a valid lesion count; 25 patients had 10 plasma treatments, and 4 patients had 8 treatments.  
\end{table} 
Table 3: Change in the number of lesions compared between the treated and the untreated side of the face.